1. Repository of OAI
Ελληνικά   English  
Saved Searches

Discover

Search


Current filters:


Clear current filters  or Add more filters

View Option


Results 1-10 of 14 (Search time: 0.004 seconds).

  Increased plasma visfatin levels in subjects with the metabolic syndrome (Journal article)

  Orlistat-associated adverse effects and drug interactions: a critical review (Journal article)

  Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome (Journal article)

  The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia (Journal article)

  The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome (Journal article)

  The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia (Journal article)

  Effects of Fenofibrate and Orlistat, Alone or in Combination, on Plasma Visfatin Levels in Subjects with Metabolic Syndrome (Journal article)

  Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia (Journal article)

  Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study (Journal article)

  Effects of Orlistat and Fenofibrate, Alone or in Combination, on Plasma Apolipoprotein C-Ii and C-Iii Levels in Metabolic Syndrome Patients (Journal article)